Neonatal herpes
Overview
Neonatal herpes is the term used when a baby develops symptoms of herpes infection before he/she is born or within the first 6 weeks of life. It may occur when the baby is still in the womb (intra uterine/congenital infection) (
Symptoms
Manifestations generally occur between the 1st and 2nd wk of life but may not appear until as late as the 4th wk. Patients may present with local or disseminated disease. Skin vesicles are common in either form, occurring in about 55% overall. Those with no skin vesicles usually present with localized CNS disease. In patients with isolated skin or mucosal disease, progressive or more serious forms of disease frequently follow within 7 to 10 days if left untreated. Photographs Neonatal Herpes Simplex Infection Neonatal Herpes Simplex Infection Neonates with localized disease can be divided into 2 groups. One group has encephalitis manifested by neurologic findings, CSF pleocytosis, and elevated protein concentration, with or without concomitant involvement of the skin, eyes, and mouth. The other group has only skin, eye, and mouth involvement and no evidence of CNS or organ disease. Neonates with disseminated disease and visceral organ involvement have hepatitis, pneumonitis, and/or disseminated intravascular coagulation with or without encephalitis or skin disease. Other signs, which can occur singly or in combination, include temperature instability, lethargy, hypotonia, respiratory distress, apnea, and seizures.
Causes
At least 4 factors increase the risk of transmission of infection from an HSV seropositive mother to the fetus or neonate: the mother has primary or initial infection during pregnancy the mother has no HSV antibodies at delivery prolonged rupture of membranes (>6 hours) (ascending infection) the use of fetal scalp monitors.
Diagnosis
Rapid diagnosis by viral culture or HSV PCR is essential. The most common site of retrieval is skin vesicles. The mouth, eyes, and CSF are also high-yield sites. In some with encephalitis, virus is found only in the brain. Diagnosis also can be made by neutralization with appropriate high-titer antiserum; immunofluorescence of lesion scrapings, particularly with use of monoclonal antibodies; and electron microscopy. If no diagnostic virology facilities are available, a Papanicolaou test of the lesion base may show characteristic multinucleated giant cells and intranuclear inclusions, but this procedure is less sensitive than culture, and false-positives also occur.
Prognosis
The mortality rate of untreated disseminated disease is 85%; among those with untreated local disease and encephalitis, it is about 50%. At least 95% of survivors have severe neurologic sequelae. Death is uncommon in those with local disease but without CNS or organ disease, except as the result of concomitant medical problems, but about 30% develop neurologic impairment, which may not manifest until 2 to 3 yr of age.
Treatment
decreases the mortality rate by 50% and increases the percentage of children who develop normally from 10 to 50%; dose is 20 mg/kg IV q 8 h for 14 to 21 days. Vigorous supportive therapy is required, including appropriate IV fluids, alimentation, respiratory support, correction of clotting abnormalities, and control of seizure disorders. Herpetic keratoconjunctivitis requires concomitant systemic acyclovir Some Trade Names ZOVIRAX Click for Drug Monograph and topical therapy with a drug such as trifluridine Some Trade Names VIROPTIC Click for Drug Monograph (see Infections in Neonates: Treatment).